Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
becaplermin (regranex) (1 trial)
allogeneic adipose derived mesenchymal stem cell (1 trial)
autologous stromal vascular fraction (1 trial)
Diabetic Foot (Phase 3)
Foot Ulcer (Phase 3)
Ischemia (Phase 2)
Ulcer (Phase 3)
Trials (2 total)
Trial APIs (3 total)